Padma Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 17-07-2024
- Paid Up Capital ₹ 9.14 Cr
as on 17-07-2024
- Company Age 44 Year, 2 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 17.75 Cr
as on 17-07-2024
- Revenue 43.60%
(FY 2023)
- Profit 64.88%
(FY 2023)
- Ebitda 39.06%
(FY 2023)
- Net Worth 2.16%
(FY 2023)
- Total Assets 2.08%
(FY 2023)
About Padma Pharmaceuticals
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.14 Cr.
The company currently has active open charges totaling ₹17.75 Cr.
Rajiv Bajaj and Shrigopal Bajaj serve as directors at the Company.
- CIN/LLPIN
U24200MH1981PTC023725
- Company No.
023725
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jan 1981
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Padma Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajiv Bajaj  | Director | 22-Dec-1983 | Current |
| Shrigopal Bajaj | Director | 21-Jan-1981 | Current |
Financial Performance of Padma Pharmaceuticals.
Padma Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 43.6% increase. The company also saw a substantial improvement in profitability, with a 64.88% increase in profit. The company's net worth moved up by a moderate rise of 2.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Padma Pharmaceuticals?
In 2023, Padma Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vital Laboratories Private LimitedActive 27 years 5 daysRajiv Bajaj and Shrigopal Bajaj are mutual person
Vital Lifesciences Private LimitedActive 21 years 1 monthRajiv Bajaj and Shrigopal Bajaj are mutual person
Charges (Loans)
₹17.75 Cr
₹0
Charges Breakdown by Lending Institutions
- Bajaj Finance Limited : 11.00 Cr
- Others : 6.75 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Feb 2019 | Others | ₹6.75 Cr | Open |
| 28 May 2015 | Bajaj Finance Limited | ₹11.00 Cr | Open |
How Many Employees Work at Padma Pharmaceuticals?
Unlock and access historical data on people associated with Padma Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Padma Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Padma Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
